Reduced HFSR incidence observed in a randomized phase II study in advanced breast cancer patients treated with sorafenib and paclitaxel by initial ramp-up dose escalation (PASO).

Overkamp, F., Steffens, C., Abenhardt, W., Lerchenmüller, C., Nusch, A., Göhler, T., Groschek, M., Hegewisch-Becker, S., Marschner, N., Rösel, S., Salat, C., Decker, T., 2011.

J Cancer Res Clin Oncol 138(Suppl.1)(0026), 62. doi:10.1007/s00432-011-1144-4